Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Paramount, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Paramount, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
San Diego, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Santa Ana, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Fort Lauderdale, FL
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Hialeah, FL
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Lauderhill, FL
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Lauderhill, FL
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Melbourne, FL
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Melbourne, FL
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Miami Springs, FL
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Miami Springs, FL
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
North Miami, FL
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
North Miami, FL
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Orange City, FL
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Orange City, FL
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Atlanta, GA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Chicago, IL
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Schaumburg, IL
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Schaumburg, IL
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
New Orleans, LA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Shreveport, LA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Glen Burnie, MD
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Glen Burnie, MD
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Toms River, NJ
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Albany, NY
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Brooklyn, NY
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
mi
from
Hope Mills, NC
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
mi
from
Hope Mills, NC
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Beachwood, OH
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Beachwood, OH
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Conshohocken, PA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Conshohocken, PA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Memphis, TN
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Desoto, TX
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Desoto, TX
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Irving, TX
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Irving, TX
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Bothell, WA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Bothell, WA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Kirkland, WA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Kirkland, WA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Spokane, WA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
mi
from
Caguas,
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
mi
from
Caguas,
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
San Bernardino, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
San Bernardino, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Saint Louis, MO
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
mi
from
Wards Island, NY
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
mi
from
Wards Island, NY
Click here to add this to my saved trials
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
Effectiveness of Acupressure Treatment in Pain Management and Fatigue Relief for Gulf War Veterans
Status: Enrolling
Updated:  10/9/2017
Cleveland Clinic
mi
from
Cleveland, OH
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
Effectiveness of Acupressure Treatment in Pain Management and Fatigue Relief for Gulf War Veterans
Status: Enrolling
Updated: 10/9/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
Biochemical, Physiological, and Psychological Measures in Normal Controls and Relatives of Psychiatric Patients
Status: Enrolling
Updated:  10/11/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
Biochemical, Physiological, and Psychological Measures in Normal Controls and Relatives of Psychiatric Patients
Status: Enrolling
Updated: 10/11/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Treatment of Smoking Among Individuals With PTSD
Treatment of Smoking Among Individuals With PTSD: A Phase II, Randomized Study of Varenicline and Cognitive Behavioral Therapy
Status: Enrolling
Updated:  10/11/2017
University of Pennsylvania School of Medicine, Dept of Psychiatry, Center for Treatment and Study of Anxiety
mi
from
Philadelphia, PA
Treatment of Smoking Among Individuals With PTSD
Treatment of Smoking Among Individuals With PTSD: A Phase II, Randomized Study of Varenicline and Cognitive Behavioral Therapy
Status: Enrolling
Updated: 10/11/2017
University of Pennsylvania School of Medicine, Dept of Psychiatry, Center for Treatment and Study of Anxiety
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Considering Healthier Drinking Options in Collaborative Care
Collaborative Care for Primary Care Patients With Alcohol Use Disorders
Status: Enrolling
Updated:  10/11/2017
Group Health Research Institute
mi
from
Seattle, WA
Considering Healthier Drinking Options in Collaborative Care
Collaborative Care for Primary Care Patients With Alcohol Use Disorders
Status: Enrolling
Updated: 10/11/2017
Group Health Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Effect of Concurrent Hookah and Alcohol Consumption on Smoking Topography and Toxicant Exposure
Effect of Concurrent Hookah and Alcohol Consumption on Smoking Topography and Toxicant Exposure
Status: Enrolling
Updated:  10/11/2017
Oklahoma Tobacco Research Center
mi
from
Oklahoma City, OK
Effect of Concurrent Hookah and Alcohol Consumption on Smoking Topography and Toxicant Exposure
Effect of Concurrent Hookah and Alcohol Consumption on Smoking Topography and Toxicant Exposure
Status: Enrolling
Updated: 10/11/2017
Oklahoma Tobacco Research Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Cognitive and Behavioral Effects of Sleep Restriction in Adolescents With ADHD
Cognitive and Behavioral Effects of Sleep Restriction in Adolescents With ADHD
Status: Enrolling
Updated:  10/11/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Cognitive and Behavioral Effects of Sleep Restriction in Adolescents With ADHD
Cognitive and Behavioral Effects of Sleep Restriction in Adolescents With ADHD
Status: Enrolling
Updated: 10/11/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Therapeutic Massage for Generalized Anxiety Disorder
Therapeutic Massage for Generalized Anxiety Disorder
Status: Enrolling
Updated:  10/11/2017
Group Health Research Institute
mi
from
Seattle, WA
Therapeutic Massage for Generalized Anxiety Disorder
Therapeutic Massage for Generalized Anxiety Disorder
Status: Enrolling
Updated: 10/11/2017
Group Health Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Pilot Trial of Peer Support for Bipolar Disorder
Pilot Trial of Peer Support for Bipolar Disorder
Status: Enrolling
Updated:  10/11/2017
Group Health Research Institute
mi
from
Seattle, WA
Pilot Trial of Peer Support for Bipolar Disorder
Pilot Trial of Peer Support for Bipolar Disorder
Status: Enrolling
Updated: 10/11/2017
Group Health Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin
Status: Enrolling
Updated:  10/12/2017
University of New Mexico, Department of Psychiatry
mi
from
Albuquerque, NM
Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin
Status: Enrolling
Updated: 10/12/2017
University of New Mexico, Department of Psychiatry
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Phase II Motivational Interviewing: An Experiential Online Training Tool
Phase II Motivational Interviewing: An Experiential Online Training Tool - SBIR - Clinical Trial
Status: Enrolling
Updated:  10/12/2017
Center For Social Innovation
mi
from
Needham, MA
Phase II Motivational Interviewing: An Experiential Online Training Tool
Phase II Motivational Interviewing: An Experiential Online Training Tool - SBIR - Clinical Trial
Status: Enrolling
Updated: 10/12/2017
Center For Social Innovation
mi
from
Needham, MA
Click here to add this to my saved trials
Multisite Prevention of Conduct Problems (Fast Track)
Multisite Prevention of Conduct Problems
Status: Enrolling
Updated:  10/12/2017
Duke University
mi
from
Durham, NC
Multisite Prevention of Conduct Problems (Fast Track)
Multisite Prevention of Conduct Problems
Status: Enrolling
Updated: 10/12/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care
CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care
Status: Enrolling
Updated:  10/12/2017
Center For Social Innovation
mi
from
Needham, MA
CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care
CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care
Status: Enrolling
Updated: 10/12/2017
Center For Social Innovation
mi
from
Needham, MA
Click here to add this to my saved trials
Increasing Treatment Adherence in Co-Occurring Psychiatric and Drug Use Disorders
Increasing Treatment Adherence in Co-Occurring Disorders
Status: Enrolling
Updated:  10/13/2017
Yale University Substance Abuse Center
mi
from
New Haven, CT
Increasing Treatment Adherence in Co-Occurring Psychiatric and Drug Use Disorders
Increasing Treatment Adherence in Co-Occurring Disorders
Status: Enrolling
Updated: 10/13/2017
Yale University Substance Abuse Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Alcohol Screening, Brief Intervention, and Referral to Treatment in a Military Treatment Facility
Feasibility and Pilot Testing of SBI to Reduce Alcohol Misuse Among Active Duty Members in a Military ER Setting
Status: Enrolling
Updated:  10/13/2017
Naval Medical Center - San Diego
mi
from
San Diego, CA
Alcohol Screening, Brief Intervention, and Referral to Treatment in a Military Treatment Facility
Feasibility and Pilot Testing of SBI to Reduce Alcohol Misuse Among Active Duty Members in a Military ER Setting
Status: Enrolling
Updated: 10/13/2017
Naval Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Integrated Eating Aversion Treatment Manual-Parent Version
Development and Assessment of iEAT for Use by Parents in the Home Setting
Status: Enrolling
Updated:  10/13/2017
Marcus Autism Center
mi
from
Atlanta, GA
Integrated Eating Aversion Treatment Manual-Parent Version
Development and Assessment of iEAT for Use by Parents in the Home Setting
Status: Enrolling
Updated: 10/13/2017
Marcus Autism Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Click here to add this to my saved trials